At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 May 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 09 Sep 1998 New profile
- 09 Sep 1998 Preclinical development for Cancer in Switzerland (Unknown route)